Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
36 search results for:

Laura Coates 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 22-08-2022 | Health services research | News | Article

    More efforts needed to improve gender equity in academic rheumatology

    For the first study, Laura Coates (University of Oxford, UK) and colleagues analyzed survey responses from 324 EULAR and Emerging EULAR Network (EMEUNET) members representing 23 of the 45 society countries as well as the USA and Mexico.

    Author:
    Claire Barnard
    Published in:
    RMD Open 2022; 8 : e002518 Lancet Rheumatol 2022; doi:10.1016/S2665-9913(22)00157-6
  2. 19-07-2022 | Bimekizumab | News | Article

    Bimekizumab demonstrates sustained benefits in PsA, ankylosing spondylitis

    For the first, Laura Coates (University of Oxford, UK) and colleagues evaluated data from 161 of 206 patients with active PsA who took part in the initial 48-week BE ACTIVE dose-ranging trial and went on to complete the subsequent 104-week open-label extension (OLE) study.

    Author:
    Claire Barnard
    Published in:
    Arthritis Rheumatol 2022; doi:10.1002/art.42280 Rheumatology 2022; doi:10.1093/rheumatology/keac353 Arthritis Rheumatol 2022; doi:10.1002/art.42282  
  3. 19-05-2022 | Psoriatic arthritis | News | Article

    Residual disease burden highlighted in people with psoriatic arthritis

    “The findings demonstrate a need for further optimisation of care for patients with PsA,” write Laura Coates (University of Oxford, UK) and co-authors in Rheumatology and Therapy .

    Author:
    Claire Barnard
    Published in:
    Rheumatol Ther 2022; doi:10.1007/s40744-022-00443-y
  4. 26-01-2022 | Psoriatic arthritis | News | Article
    approvalsWatch

    FDA approves risankizumab for psoriatic arthritis

    Click through to watch Laura Coates discuss how risankizumab may fit in the treatment landscape for psoriatic arthritis Commenting on the announcement, Saakshi Khattri (Mount Sinai Hospital, New York, USA) says that the approval of the risankizumab “is great news because it adds another biologic treatment to our arsenal to better care for our patients with skin and joint symptoms.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

    Author:
    Claire Barnard
  5. 06-11-2021 | ACR 2021 | Conference coverage | Article

    KEEPsAKE trials show benefits of risankizumab in patients with PsA

    Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis (5.10).

    Author:
    Claire Barnard
    Published in:
    ACR Convergence 2021; 3–9 November
  6. 12-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | Article

    Continuing ixekizumab superior to withdrawal for stable psoriatic arthritis patients

    The relapse rate for patients who achieved MDA after 24 weeks of open-label treatment and continued to take the interleukin (IL)-17a inhibitor for 40 weeks was 34%, which was significantly lower than the 73% rate seen among patients who received placebo instead, reported Laura Coates, from the University of Oxford in the UK.

    Published in:
    Arthritis Rheumatol  2019; 71 (suppl 10) ACR/ARP 2019; Atlanta, Georgia, USA: 8–13 November
  7. 22-10-2019 | Teaser
    ACR/ARP 2019 clinical trial recommendation

    Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study

    Sunday,   November 10, 17:00–17:15. Georgia World Congress Center, Atlanta, USA Presenting author:  Irene van der Horst-Bruinsma, Netherlands TRIAL RESULTS PUBLISHED  | Read the full story What our Advisory Board said: This is an important analysis for those treating resistant uveitis where certolizumab may have shown efficacy. – Laura Coates, UK

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.